Related Experiment Video
Updated: Mar 26, 2026
Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics
Published on: March 15, 2024
Cell-Line Selectivity Improves the Predictive Power of Pharmacogenomic Analyses and Helps Identify NADPH as Biomarker
Kenichi Shimada1, Miki Hayano2, Nen C Pagano1
1Department of Biological Sciences, Columbia University, New York, NY 10027, USA.
Abstract:
Precision medicine in oncology requires not only identification of cancer-associated mutations but also effective drugs for each cancer genotype, which is still a largely unsolved problem. One approach for the latter challenge has been large-scale testing of small molecules in genetically characterized cell lines. We hypothesized that compounds with high cell-line-selective lethality exhibited consistent results across such pharmacogenomic studies. We analyzed the compound sensitivity data of 6,259 lethal compounds from the NCI-60 project. A total of 2,565 cell-line-selective lethal compounds were identified and grouped into 18 clusters based on their median growth inhibitory GI50 profiles across the 60 cell lines, which were shown to represent distinct mechanisms of action. Further transcriptome analysis revealed a biomarker, NADPH abundance, for predicting sensitivity to ferroptosis-inducing compounds, which we experimentally validated. In summary, incorporating cell-line-selectivity filters improves the predictive power of pharmacogenomic analyses and enables discovery of biomarkers that predict the sensitivity of cells to specific cell death inducers.
Insights
This study enhances precision medicine by identifying selective lethal compounds and discovering NADPH abundance as a biomarker for ferroptosis-inducing drug sensitivity in cancer.
Area of Science:
- Oncology
- Pharmacogenomics
- Molecular Biology
Background:
- Precision medicine in oncology necessitates matching cancer genotypes with effective drugs, a significant unmet need.
- Large-scale compound screening in cell lines is a key strategy for identifying potential cancer therapeutics.
Purpose of the Study:
- To investigate if cell-line-selective lethality improves pharmacogenomic analysis consistency.
- To identify biomarkers predicting drug sensitivity, specifically for ferroptosis-inducing agents.
Main Methods:
- Analyzed compound sensitivity data for 6,259 lethal compounds from the NCI-60 project.
- Clustered 2,565 cell-line-selective lethal compounds based on growth inhibitory profiles (GI50).
- Performed transcriptome analysis to identify predictive biomarkers and experimentally validated findings.
Main Results:
- Identified 2,565 cell-line-selective lethal compounds, clustered into 18 groups representing distinct mechanisms of action.
- Discovered NADPH abundance as a predictive biomarker for sensitivity to ferroptosis-inducing compounds.
- Demonstrated improved predictive power of pharmacogenomic analyses using cell-line-selectivity filters.
Conclusions:
- Cell-line-selectivity filters enhance the predictive accuracy of pharmacogenomic studies.
- Biomarker discovery, such as NADPH abundance, aids in predicting cellular responses to specific cell death inducers.
- This approach advances the development of targeted cancer therapies.
More Related Videos
08:46Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
09:21Ferritinophagy: Assessing the Selective Degradation of Iron by Autophagy in Human Fibroblasts
Published on: February 23, 2024
Related Concept Videos
01:29Pharmacogenomics: Identification of New Drug Targets
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase